|
Sidec Technologies AB, Sweden, today announced a contract research
collaboration with Procognia Ltd, UK, to locate protein glycosylation
sites.
Sidec’s 3-D reconstruction technology for protein imaging will be used
to determine the location of glycosylation sites on proteins supplied
by Procognia.
Sidec has developed a technology for 3-D reconstruction of multiple
protein structures in a single analysis. This technology has the
potential to provide a rapid tool for locating glycans on intact
glycosylated proteins. Current glycan localization processes requires
cleavage of the protein and extensive purification and analysis of the
protein fragments.
It is well known that differences in the glycosylation of proteins can
have profound effects on their biological properties. Yet, the
glycosylation on biopharmaceutical products is one of the most
difficult manufacturing processes to control. Procognia has developed
a technology for the rapid analysis of glycosylation patterns of
intact proteins in a mixture of glycoforms.
If the 3-D technology is successful in visualizing the location of
glycans on intact proteins, it may obviate more complicated analyses
required to obtain that information using current technology.
Therefore, Procognia’s technology could be complimented by a means of
rapidly determining the location of the glycosylation sites. Sidec’s
3-D reconstruction with SET (Sidec™ Electron Tomography) coupled with
Procognia’s U-c fingerprint of protein glycosylation patterns has the
potential to be important in the discovery, development and
manufacture of protein-based pharmaceuticals.
“SET has already been proven useful in industrial projects, to
characterize proteins and protein interactions. We are now seeking new
applications, and together with Procognia we aim at speeding up and
facilitating the analysis of protein glycosylations”, says Mr. Gösta
Sjöholm, Sidec’s Chief Executive Officer.
Sidec Technologies AB provides solutions for 3-D imaging of biomolecules, based on the company’s proprietary technology. Sidec™
Electron Tomography (SET) allows for visual characterization of
proteins in membranes or in solutions. By portraying the molecules in
a “frozen moment in time” the company extracts information about e.g.
binding domains and the mechanisms behind protein interactions. Sidec
is a privately held company originating from the Karolinska Institute,
and located in Stockholm, Sweden. Initially, the company will focus on
protein characterization at the drug discovery and development market.
The technology is offered for contract research, where 3-D images are
delivered from customer samples. For more information, please visit
www.sidectech.com.
Procognia is developing a suite of technological solutions to needs
arising in pharmaceutical drug discovery, development and manufacture.
It has developed integrated, rapid glycoanalysis technologies to
increase the probability of success of biopharmaceutical products.
Procognia technology is an automated process that can perform
glycoanalysis in a few hours. The ability to perform ‘real time’
analysis of glycosylation patterns during clone selection and
optimization, process development, manufacture and QC have the
potential to greatly improve both the number and quality of biologic
drugs. For more information, please visit www.procognia.com
Statements in this press release that are not strictly historical are
"forward-looking" statements, which involve a high degree of risk and
uncertainty. Such statements are only predictions, and the actual
events or results may differ materially from those projected in such
forward-looking statements.
Fur further information, please contact:
Sidec Technologies AB
CEO
Tel: +46 8 508 845 21
E-mail: gosta.sjoholm@sidectech.se
Marketing
Tel: +46 8 508 845 23
E-mail: malin.engstrom@sidectech.se
Procognia Ltd
CCO
Tel: +1 610-321-2520
E-mail: johanna.griffin@procognia.com
|
|
